BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Posts Quarterly Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced its quarterly earnings data on Tuesday. The company reported ($705.20) EPS for the quarter, FiscalAI reports.

BridgeBio Oncology Therapeutics Stock Up 0.2%

BBOT traded up $0.02 during trading hours on Wednesday, hitting $9.22. 41,962 shares of the company’s stock were exchanged, compared to its average volume of 360,161. The stock has a market cap of $738.59 million, a price-to-earnings ratio of -4.50 and a beta of 0.36. BridgeBio Oncology Therapeutics has a 1-year low of $7.00 and a 1-year high of $14.87. The stock’s 50-day moving average is $8.22 and its two-hundred day moving average is $9.11.

Institutional Trading of BridgeBio Oncology Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Granahan Investment Management LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics in the 1st quarter valued at approximately $2,068,000. Catalio Capital Management LP bought a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $5,142,000. Armistice Capital LLC increased its stake in shares of BridgeBio Oncology Therapeutics by 142.7% during the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $12,520,000 after purchasing an additional 588,000 shares during the last quarter. BIT Capital GmbH bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $313,000. Finally, XTX Topco Ltd increased its holdings in shares of BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock worth $358,000 after acquiring an additional 5,249 shares during the last quarter. Institutional investors own 54.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BBOT shares. UBS Group cut BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. JPMorgan Chase & Co. began coverage on BridgeBio Oncology Therapeutics in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $27.00 target price for the company. Wall Street Zen raised BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th. Finally, Oppenheimer started coverage on BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They set an “outperform” rating and a $22.00 target price for the company. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, BridgeBio Oncology Therapeutics has an average rating of “Moderate Buy” and an average price target of $24.80.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.